Skip to main content
European Commission logo print header

Neurodegeneration in Alzheimer's disease - mechanisms, consequences and therapy


The aim of this project is to provide structured research training for early stage researchers in the field of Neurosciences, with special emphasis on Alzheimer's disease (AD). Due to the demographical development of societies in industrialized countries, the number of AD patients will increase dramatically within the next years.

Thus, the demand for well-trained scientists in pharmaceutical companies and academic research units focussing on AD is expected to rise. To be able to meet the future requirements, a consortium of AD scientists from 9 universities have gathered to implement a Marie Curie Early Stage Training, named NEURAD (acronym for "neuron" and "AD") together with one pharmaceutical company and two SMEs.

The common theme of the consortium is to study the early patho-mechanisms of AD, the consequences for the physiology of neuronal networks and for deficits in memory, with the implementation and verification of novel therapeutic approaches for AD being one of its main targets.

The fellows will be trained in four complementary modules.

- Interdisciplinary experimental training in another university based laboratories within the consortium for at least 6 months.
- Multidisciplinary courses in AD research and management skills during an annual two-week summer school as complementary training.
- An intersectional 3 months research training in a laboratory of the pharmaceutical partners.

- One-month clinical internship in a clinical memory unit. These actions will manifest the mobility of the fellows in a European perspective, and implement the truly interdisciplinary, interscectional and multidisciplinary character of the NEURAD initiative.

Call for proposal

See other projects for this call




See on map

EU contribution
€ 0,00

Participants (11)